Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

BVI Announces CE Mark Under EU MDR for Virtuoso®, A Brand New Dual-Function Surgical Platform

BVI has achieved CE Mark certification for its Virtuoso® dual-function phaco-vitrectomy platform, designed to enhance control and efficiency in both cataract and vitreoretinal surgeries. This milestone was marked by the successful treatment of the first patient at LMU Klinikum in Munich, Germany, in December 2025. The platform’s introduction at key industry forums throughout 2025 and into 2026, including its first live surgery at the Munich Retina Meeting, underscores its innovative design focused on fluidics stability and workflow efficiency.

The Virtuoso® platform integrates several advanced features, such as the Equality™ Fluidics Control for consistent intraocular pressure management, and the Resolute™ Ultrasound Delivery system that optimizes energy delivery based on lens hardness. The Velvet™ Vitrectomy Probe and EvenFlow™ Automatic FAX further enhance surgical efficiency, addressing the complex needs of multi-specialty centers. Clinical evaluations led by Professor Siegfried Priglinger at LMU Klinikum have already highlighted the platform’s responsiveness and stability during surgeries, with findings indicating improved aspiration efficiency and energy delivery consistency compared to leading systems.

The introduction of Virtuoso® may significantly shift current paradigms in ophthalmic surgery, emphasizing the need for integrated platforms that cater to both anterior and posterior procedures. As commercial availability is expected in Q3 2026, this development not only positions BVI competitively within the premium surgical equipment market but also aligns with broader trends towards versatile, cost-effective solutions in surgical environments. The platform’s design and functionality could accelerate the adoption of advanced surgical techniques, ultimately enhancing patient outcomes in eye health.

Source: globenewswire.com